DDU of Soft Mist Inhalers (SMIs)

Both MDIs and DPIs suffer from the same two inherent problems: low lung deposits (typically 5-20%) and dose variability (often due to patient difficulties in coordination or inspiration).SMIs (often known as “Inhalation Metered Sprays’’ or “Aqueous Droplet Inhalers”) actively aerosolise the liquid, forming a ‘soft mist’ to overcome these problems. These inhalers generally deliver a higher fine particle fraction than MDIs or DPIs. However, as with any multi-dose liquid system, microbial contamination can be a problem. Since they are active, aqueous-based devices, the DDU testing of ADIs is similar to that of MDIs, with testing carried out at a constant flow rate of 28.3 L/min.

DDU of Dry Powder Inhalers (DPIs)

DDU Over the Entire Contents

In the case of multiple dose devices, tests might need to be carried out throughout the life of the inhaler i.e. dose uniformity over the entire contents.

Learn More

Related Applications

We also offer a range of equipment for additional MDI testing application support:

Semi-Automation Tools

Improve efficiency
Reduce variability
Eliminate handling errors
Increase testing capacity

Related Services

Related News & Resources

Copley introduces the new Flow Rate Sensor, a dedicated device for inhaler testing systems.

27th June 2023

Find out more

The new DUSA Shaker™ DTS 100i from Copley: For faster, safer, more repeatable inhaler testing

8th February 2023

Find out more

Copley launches EnviroMate™, an efficient, benchtop environmental chamber for inhaler testing

14th September 2022

Find out more

Copley Scientific joins the Industries Forum of the Taskforce for Lung Health

22nd June 2021

Find out more

Copley announces a major upgrade of the world’s ‘go to’ inhaler testing portfolio

1st March 2021

Find out more

New e-Training service from Copley for pharmaceutical testing

29th January 2021

Find out more

Advancing the science of OINDPs: Copley Scientific joins IPAC-RS

28th February 2018

Find out more

Understanding the Links Between Drug Delivery Route and In Vitro Test Methods

View download

Reducing Inhaler Testing Variability Through Test Environment Control

View download

Semi-Automating Inhaler Testing – A Good Idea, but Where to Start?

View download

A short Q&A with our CEO, Mark Copley, On Inhaled Product Testing

View download

Optimizing the Role of Automation in Variability Reduction Strategies For Delivered Dose Uniformity (DDU) and Aerodynamic Particle Size Distribution (APSD) Testing of Inhaled Drug Products

View download

The Regulatory Landscape for OINDPs – The Biggest Shake-up in A Generation?

View download

Optimizing the Application of In Vitro Test Methods for the Demonstration of Bioequivalence in Orally Inhaled Products

View download

Demonstrating Bioequivalence of Orally Inhaled Products

View download

Optimising the Application of In Vitro Test Methods for the Demonstration of BE in OIPs

View download